NIO Launches ONVO L90, a Family-Centric Electric SUV With 605 KM Range
Warning! GuruFocus has detected 4 Warning Signs with NIO.
China will receive deliveries on August 1. The SUV has a 900V basis and a family-friendly cabin. L90 has a 5,145-mm length and 3,110-mm wheelbase. The cabin is 4,195 mm long and includes 670 liters of rear and 240 liters of front storage. The most space in a Chinese electric vehicle.
Normal 85 kWh batteries can take the automobile 605 kilometers. The two-wheel-drive model uses 14.5 kWh/100 km. The all-wheel-drive model has 440 kW and reaches 100 km/h in 4.7 seconds.
NIO has 3,400 battery swaps and 4,659 recharge stations in 550 Chinese sites. The L90 leverages this network to help long-distance travelers with range issues.
The body is 84% aluminum alloy and ultra-high-strength steel, with nine airbags and a 2.92-meter side curtain airbag system. The 2024 C-NCAP and C-IASI five-star safety standards were met by the L90.
Inside, customers can choose six or seven seats and three themes. Also included are ambient lights and titanium accents. The L90 has the NT.Coconut 2.0 ONVO Smart System. It manages the smart interior, car controls, and driving.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Uncertainty is 'here to stay': What that means for markets
PIMCO chief investment officer core strategies Mohit Mittal joins Market Domination with Josh Lipton and Hennion & Walsh chief investment officer Kevin Mahn to discuss President Trump's upcoming August 1 tariff deadline, the uncertainty that comes with it, and why "the balance of risk" is shifting to the downside. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Joining us now is Mohit Mittal, he's chief investment officer, core strategies at Pimco. That firm has more than two trillion dollars in assets under management. Mohit, it is great to see you on the show. Maybe start, Mohit, with what we were just talking about there: trade tensions, tariffs. We have August 1st that is circled on our calendars. As investors we're all waiting for it. I'm curious to think about how are you thinking through that deadline? As a CIO, what are you telling clients? Thanks for having me, Josh. Yes, so, I think the way we are thinking about this, even if we take a step back from that one immediate deadline, what we are observing is a broad, somewhat slowdown in the data. Add to it the incredible amount of uncertainty that is being created by these broad tariff policies. And those uncertainties are not going to go away on August 1st. Meaning that there might be some extensions, there might be some deals, but those uncertainties are here to stay. And what that means is that that uncertainty feeds into corporate sentiment. That uncertainty feeds into consumer sentiment. Which means that, you know, as we go forward towards the end of the year or next year, growth continues to slow down towards, say, 1%. And then add to it the context around earnings expectations. So when you look at the earnings expectations for this year, they are in the high single digits, same for next year. So the balance of risk in our mind, given kind of these uncertainties and in the context of expectations which are quite optimistic, the balance of risk seems to be towards kind of under-delivering relative to expectations. So is your point, and I'm just looking at the popular average here, we are, you know, agreeing across the board. Again, Mohit, is your point that you think investors are being a bit complacent here? Absolutely. I think that's kind of the view here that investors are being complacent in, say for example, kind of the equity markets, even in lower quality segments of the credit markets where valuations are near historic types. And when we contrast that to higher quality fixed income where investors can get, call it, six percent yield in a very, very high quality manner. That looks like a very attractive alternative in this kind of environment of elevated uncertainty and ongoing complacency. Kevin, bring you in here as well. Mohit's point is well taken. To the extent, Kevin, I wonder whether you get nervous when nobody else seems to be nervous. Absolutely, and I think what we need to understand is that we're pretty far along this bull market run. Through the first 73 trading days of 2025, the S&P 500 was down 10.2%, the fifth worst start in history. Now we've seen a significant move higher since day 74. How much longer can that run last? So I would anticipate some more short-term bouts of volatility ahead, whether it's due to the lack of trade agreements being announced, perhaps tariffs being more severe than when originally anticipated, or the Fed staying on pause for even longer than many are currently forecasting right now. That could all create more volatility. But I think each part of that volatility brings more investors back into the market. Mohit, what do you say to those folks who come on the show and they're, they're bulled up, they're more constructive. And honestly, Mohit, I think they basically tell me, 'Listen, Josh, just don't overthink this. The reason the market's higher is because the fundamentals look good: solid earnings, solid economic data, and a Fed that seems to want to cut later in the year.' What is your response to that? I think there's a lot of merit to that and that certainly can hold that we can continue to see, you know, equity markets do well. We continue to see credit markets do well. But I think what is also interesting is that in the last, call it, 15, 17 years, post the GFC, generally buying the dip has always worked out. And I think many factors have been behind it, but one of the factors continues to be around ongoing large fiscal deficits, as well as a strong monetary policy support through quantitative easings. Whenever there has been a big stress, you have seen both the fiscal authorities as well as monetary authorities come to the rescue. I think where we are, as we think about kind of where we are, we recognize that because of high debt to GDP for the US federal government, you have some constraints at the fiscal level in order to be able to address the next crisis with larger fiscal deficits. Same thing, you know, with the Central Bank. I think the QE would be somewhat less easier to do next time around, given the prior inflation or concerns around inflation that the prior QEs may have created. So in that context, we recognize that I think certainly you could have an environment where earnings continue to deliver and equities do well, but the balance of risk seems to have shifted to the downside. And I think the last point I would highlight also is that a lot of optimism is being built around the idea that we will realize the productivity enhancements because of all the investments in AI related chips, energy, all of that. In a scenario we don't realize those productivity enhancements, I think certainly the balance of risk again shifts a little bit to the downside. Related Videos Mortgage rates steady, Trump says no capital gains on home sales Why bitcoin could hit $300,000 next year 4 advantages give Alphabet a 'strategic position' in AI race Pharma sector outlook as Trump's drug tariff deadline looms Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Pharma sector outlook as Trump's drug tariff deadline looms
Pharmaceutical stocks are in focus as President Trump's drug tariff deadline looms. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination with Josh Lipton to discuss the impact that pharmaceutical tariffs could have on the sector, Astrazeneca's (AZN) $50 billion commitment to US investments, and how the industry is navigating pressure from Washington and shifting global demand. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Pharmaceutical stocks in focus as we approach President Trump's looming drug tariff deadline. For more, I want to bring in Yahoo Finance senior health reporter Angelique Chenge. That's right, Josh. With that looming deadline, potentially August 1st, for up to 200% in tariffs, we don't know what that number will actually end up being. We've heard from several companies that have announced manufacturing commitments in hopes to thwart that effort. That includes AstraZeneca. We spoke to CEO Pascal Soriot about that, and he did mention that the announcement for $50 billion, that's in addition to $3.5 billion last year, is in part a response to Trump's tariffs. We know others like Eli Lilly and Johnson & Johnson have also announced similarly big announcements of commitments for manufacturing. And this is in play at a time where the industry is also going through a bit of tumult. We know that there is a lot of investment in one of Trump's least favorite countries, that is China. That is the reason why there has been a lot of tension in the biotech world. We also know that big pharma has been pivoting and investing there as well. Licensing deals and the like are on the rise as they look to sort of respond to all the different countries that are looking for what has now been termed health sovereignty. And this plays into that. So, when I asked Pascal about that, about China and the deal making there, here's what he had to say about it. We believe that it's our ethical responsibility to bring medicines to as many people as possible. Of course, there are limitations to what we can do, but we work very hard to do this. And we are lucky enough or good enough or both, that we are growing. And growth brings opportunities. And because we are growing, we are able to invest in United States for the United States, we're able to invest in China for China, and we're also able to seek innovation where it happens. Because actually, if innovation happens in China or in Europe, we need to take this innovation, develop it, and bring it to patients for instance in the United States, but manufacture the product in the United States. Um, and I think that brings me to an important point that people don't talk enough about is that today innovation in our industry takes place in the U.S. U.S. is the biggest innovator for biopharmaceuticals. And it's really important that everything is done to protect that innovation. It's a fantastic engine to bring new medicines to patients but also create good jobs, well-paid jobs, and economic growth. So, as you can hear, a lot of focus on that, on economic growth being the driver as well and needing to respond to these countries and their efforts. AstraZeneca also talked about how it would help shift revenues for the portfolio with a greater reliance on the U.S. Currently, 42% of revenues comes from the U.S. And with this increase in manufacturing, it would be 50%. And that includes GLP-1s. We know that there's a lot of global demand for that drug and for those types of drugs. AstraZeneca has been pursuing an oral form or pill form, which is largely seen as the next frontier in this space. AstraZeneca looking at being able to then supply the rest of the world from the U.S., making it a larger exporter. So, here's what Pascal said about that. It's also a reason, another reason why we are investing in this very large facility. We have our oral GLP-1. Everybody knows GLP-1 by now. These are agents used to help people manage their weight. We have an oral agent, and we have bet on oral agents because we think they are going to be easier for patients, because they will be cheaper, they'll be more accessible, and we will be able to export them around the world, not only supply America. But we also have other products treating cardiovascular metabolic disease. We have a new agent for hypertension for patients who are not controlled on multi-medicines. We have an oral PCSK9 for the control of cholesterol and many others. Cardiovascular metabolic diseases are the biggest killer in the world today, including in the United States. So, you can see the needs are enormous. This plant will supply products for American patients, so American patients will access products that are American-made. But this plant will also export to the billions of patients around the world who need these medicines. The company really moving that pot of money, you know, globally and looking at where it makes the most sense. Pascal also did tell me that in looking at the different areas of the world where the money can be, you know, invested, China, of course, being one of them. And then if you compare the amount that has been put in there, that is $5.3 billion is one of the latest deals that AstraZeneca has done in China. And if you compare that to the $50 billion, while not on the same level, you can still see it's quite a large number. And that's just one of those deals. So, we're starting to see a little bit of bifurcation in how the global pharmaceutical economy is functioning. Related Videos Uncertainty is 'here to stay': What that means for markets BlackRock's Rick Rieder: I Think Rates Can Come Down Elon Musk's 'master plan': Is Tesla an EV maker or AI play? 'We ask for more data' than FICO: VantageScore CEO Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
These Old Coins and Banknotes Are Selling For More Than Real Estate
Some old coins and banknotes are selling for more than the cost of a home. These collectibles are drawing six-figure bids from buyers, pushing them into the same conversation as traditional investments like real estate. The right item, authenticated and auctioned, can deliver an outsized return, all without the maintenance, taxes or paperwork that come with owning property. Check Out: Read Next: Kuang-Hsü Tael (1906) In June 2025, a rare Chinese silver coin called the Kuang-hsü Tael from the Peh Family Collection sold for $810,000 at a Heritage Auctions event, according to CoinWeek. It's a coin few people have ever held in person, but collectors were willing to pay more than the average home price in cities like Austin ($523,769), Denver ($555,304) and Salt Lake City ($571,623). More Collectibles: Long-Whiskered Dragon Dollars (1911) The Peh Family Collection also produced two highly sought-after 1911 'Long-Whiskered Dragon' silver dollars that set auction records. A 'Restrike Specimen Pattern Long-Whiskered Dragon Dollar Year 3' (1911) graded SP63 by NGC sold for $504,000, while a nearly identical piece, graded SP63+, went for $408,000 — both fetching more than the average home price in Tucson ($331,789) or Jacksonville ($290,108). Netherlands Bank 100 Gulden Note (1814-1838) At the same auction, a Dutch banknote fetched $114,000. It wasn't gold, and it wasn't flashy, but it was rare and in great condition. For perspective, that single piece of paper sold for more than the average home in Detroit ($78,601). Why Collectibles Are Beating Property A decent home in a mid-sized city might take 90 days or more to sell. The seller covers taxes, agent commissions, repairs and closing costs. And unless it's in a booming market, the return often creeps up slowly, if at all. Compare that to the collectibles market. A coin can be shipped to an auction house, authenticated and sold to a global bidder base in days. No yard signs or home inspections, and a rare item in pristine condition can get instant interest and a fast sale. And while real estate is often limited by location, collectibles aren't. A coin stored in a desk drawer in New Jersey can sell to a buyer in Tokyo or Dubai without ever changing hands physically. That kind of mobility and liquidity makes coins and notes increasingly attractive, especially when markets are uncertain. Editor's note: Average home prices were sourced from More From GOBankingRates Mark Cuban Warns of 'Red Rural Recession' -- 4 States That Could Get Hit Hard The 10 Most Reliable SUVs of 2025 How Far $750K Plus Social Security Goes in Retirement in Every US Region This article originally appeared on These Old Coins and Banknotes Are Selling For More Than Real Estate Sign in to access your portfolio
